@article{ModicaAltieriD’Anielloetal.2023,
  author    = {Modica, Roberta and Altieri, Barbara and D'Aniello, Francesco and Benevento, Elio and Cannavale, Giuseppe and Minotta, Roberto and Liccardi, Alessia and Colao, Annamaria and Faggiano, Antongiulio},
  title     = {Vitamin D and bone metabolism in adult patients with neurofibromatosis type 1},
  series = {Metabolites},
  volume    = {13},
  journal   = {Metabolites},
  number    = {2},
  issn      = {2218-1989},
  doi       = {10.3390/metabo13020255},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-303957},
  year      = {2023},
  abstract  = {Neurofibromatosis type 1 (NF1) is a genetic multisystemic autosomal dominant disorder determining reduced life expectancy due to higher risk of developing benign and malignant tumors. Low levels of vitamin D and reduced bone mineral density (BMD) have been reported in young patients with NF1. However, correlation between vitamin D and NF1 phenotype needs to be elucidated. Aim of this study was to assess vitamin D levels and bone metabolism in NF1 patients, analyzing potential correlations with clinical phenotype. A cross-sectional study was carried out in a monocentric series of NF1 patients, evaluating genotype, clinical phenotype, BMD, biochemical evaluation with focus on serum 25OH-vitamin D, parathyroid hormone (PTH), calcium and phosphate levels. Correlations between clinical manifestations, neurofibromas, and vitamin D status have been studied in comparison with healthy controls. 31 NF1 adult patients were matched for sex, age and body mass index with 31 healthy controls. A significantly difference in vitamin D level emerged in NF1 patients compared to controls. Interestingly low vitamin D levels correlated with a more aggressive phenotype and with a bigger size of neurofibromas. These data underline that vitamin D deficiency/insufficiency may play a role in clinical severity of neurofibromas in patients with NF1, suggesting the need to check bone status and replace vitamin D in these patients.},
  language  = {en}
}
@article{GoetzRueckschlossBalketal.2023,
  author    = {G{\"o}tz, Lisa and Rueckschloss, Uwe and Balk, G{\"o}zde and Pfeiffer, Verena and Erg{\"u}n, S{\"u}leyman and Kleefeldt, Florian},
  title     = {The role of carcinoembryonic antigen-related cell adhesion molecule 1 in cancer},
  series = {Frontiers in Immunology},
  volume    = {14},
  journal   = {Frontiers in Immunology},
  doi       = {10.3389/fimmu.2023.1295232},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-357250},
  year      = {2023},
  abstract  = {The Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), also known as CD66a, is a member of the immunoglobulin superfamily. CEACAM1 was shown to be a prognostic marker in patients suffering from cancer. In this review, we summarize pre-clinical and clinical evidence linking CEACAM1 to tumorigenicity and cancer progression. Furthermore, we discuss potential CEACAM1-based mechanisms that may affect cancer biology.},
  language  = {en}
}